Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer
NCT ID: NCT00811369
Last Updated: 2013-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
126 participants
INTERVENTIONAL
2009-08-31
2013-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In summary, women with bone only, or bone predominant, metastatic breast cancer is an ideal group to study anti-angiogenic therapies where angiogenesis could be a major factor in tumor progression and where anti-angiogenic treatment with agents like ZACTIMA could be more effective.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Fulvestrant + ZACTIMA Group
Fulvestrant + ZACTIMA
ZACTIMA 100 mg tablets. Dose = 1 tablet daily until disease progression or intolerance
2
Fulvestrant + Placebo Group
Fulvestrant + Placebo
ZACTIMA Placebo 100 mg tablets. Dose = 1 tablet daily for duration of study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fulvestrant + ZACTIMA
ZACTIMA 100 mg tablets. Dose = 1 tablet daily until disease progression or intolerance
Fulvestrant + Placebo
ZACTIMA Placebo 100 mg tablets. Dose = 1 tablet daily for duration of study.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age greater than or equal to 60 years or
* Age greater than or equal to 45 years with amenorrhea more than 12 months with an intact uterus or
* Follicle-stimulating hormone (FSH) levels in postmenopausal range or
* Having undergone a bilateral oophorectomy
2. Metastatic breast cancer with either radiologically confirmed bone only or predominant metastases to bone not considered amenable to curative treatment.
3. Evidence of hormone sensitivity either ER+ and/or PgR+, as per institutional standards, in the primary tumor.
4. Patients must fulfill one of the following RECIST criteria:
* Bone lesions, which are lytic, sclerotic or mixed (lytic + sclerotic), in the absence of measurable disease as defined by RECIST criteria or
* Bone lesions, which are lytic, sclerotic or mixed (lytic + sclerotic), in the presence of measurable disease as defined by RECIST criteria.
5. Patients must fulfill one of the following resistances to endocrine therapy criteria:
* Disease progression on tamoxifen or on an aromatase inhibitor as first or second line therapy for metastatic disease or
* Development of metastatic disease while on treatment with tamoxifen or an aromatase inhibitor in the adjuvant setting or
* Disease progression after discontinuation of prior adjuvant endocrine therapy.
Exclusion Criteria
2. History of hypersensitivity to active or inactive excipients of fulvestrant and/or ZACTIMA.
3. Has received greater than one line of systemic chemotherapy for metastatic breast cancer.
4. Has received chemotherapy within the past 14 days (+ 2 days).
5. Has received radiation therapy within the past 14 days (+ 2 days).
6. Has undergone major surgery within the past 21 days or has had major surgery performed \> 21 days prior to screening and the wound remains unhealed.
7. Has received LH-RH agonist within the past 4 months.
8. Prior treatment with VEGF inhibitors (prior use of AVASTIN permitted).
9. Current or previously active systemic malignancy within 3 years prior to randomization (other than breast cancer, or adequately treated in-situ carcinoma of the cervix, uteri, or basal or squamous cell carcinoma of the skin).
10. Presence of life-threatening metastatic visceral disease, defined as extensive hepatic involvement, or any degree of brain or leptomeningeal involvement (past or present), or symptomatic pulmonary lymphangetic spread. Patients with discrete pulmonary parenchymal metastases are eligible, provided their respiratory function is not compromised as a result of disease.
11. ECOG performance status of \> 2.
12. Currently receiving (and are unwilling to discontinue) hormone replacement therapy.
13. Laboratory results sustained at:
* Platelets \< 100 x 109 /L
* International normalized ratio (INR) \> 1.6
* Total bilirubin \> 1.5 times normal
* ALT or AST \> 2.5 times normal range if no demonstrable liver metastases or \> 5 times normal range in the presence of liver metastases. No more than three retests within screening period are allowable.
14. Potassium level outside of normal range, despite supplementation; serum calcium (or ionized or adjusted for albumin), or magnesium below the lower limit of the normal range despite supplementation or creatinine clearance \< 30mL/min.
15. History of:
* Bleeding diathesis (i.e. disseminated intravascular coagulation \[DIC\], clotting factor deficiency) or
* Long-term anticoagulant therapy (other than anti-platelet therapy).
16. Any severe concomitant condition which makes it undesirable for the patient to participate in the study or which would jeopardize compliance with the protocol, e.g. severe renal or hepatic impairment or currently unstable or uncompensated respiratory or cardiac conditions, ongoing or active infection, untreated primary hyperparathyroidism, or psychiatric illness that would limit compliance with study requirements.
17. Anticipated life expectancy less than six months.
18. Non-approved/experimental drug treatment within previous 4 weeks before randomization.
19. Significant cardiovascular event (e.g., myocardial infarction, superior vena cava syndrome), New York Heart Association (NYHA) classification of heart disease (Appendix II) \> Class II within 3 months before study entry, or presence of cardiac disease that in the opinion of the investigator increases the risk of ventricular arrhythmia.
20. History of arrhythmia (multifocal premature ventricular contractions (PVCs), bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) which is symptomatic or requires treatment (NCI CTCAE Grade 3 or 4) or asymptomatic sustained ventricular tachycardia. Atrial fibrillation, controlled on medication, is not excluded.
21. Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age.
22. QT prolongation with other medications that required discontinuation of that medication.
23. Presence of left bundle branch block (LBBB).
24. QTc with Bazett's correction measurable at \> 480msec on screening ECG. (Note: If a patient has QTc \> 480msec on screening ECG, the screen ECG may be repeated twice (at least 24 hours apart). The average QTc from the three screening ECGs must be \< 480msec in order for the patient to be eligible for the study). Patients who are receiving a drug that has a risk of QTc prolongation (see Appendix III, Table 2) are excluded if QTc is \> 460msec.
25. Hypertension not controlled by medical therapy (systolic blood pressure \> 160 millimeter of mercury (mmHg) or diastolic blood pressure \> 100mmHg).
26. Concomitant medications that are potent inducers (rifampicin, rifabutin, phenytoin, carbamazepine, phenobarbital and St. John's Wort) of CYP3A4 function.
27. Not accessible for treatment and follow up.
28. Failure to provide informed consent.
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Ontario Clinical Oncology Group (OCOG)
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark Clemons, MD
Role: PRINCIPAL_INVESTIGATOR
The Ottawa Hospital Regional Cancer Centre
Rebecca Dent, MD
Role: PRINCIPAL_INVESTIGATOR
Odette Cancer Centre - Sunnybrook Health Sciences Centre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cross Cancer Institute
Edmonton, Alberta, Canada
British Columbia Cancer Agency - Vancouver Centre
Vancouver, British Columbia, Canada
QE II Health Sciences Centre
Halifax, Nova Scotia, Canada
Regional Cancer Program of the Hôpital régional de Sudbury Regional Hospital
Greater Sudbury, Ontario, Canada
Juravinski Cancer Centre
Hamilton, Ontario, Canada
Grand River Regional Cancer Centre
Kitchener, Ontario, Canada
RSM Durham Regional Cancer Centre
Oshawa, Ontario, Canada
Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
Odette Cancer Centre - Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
St. Michael's Hospital
Toronto, Ontario, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
Centre Hospitalier De L'Universite De Montreal - Hotel Dieu
Montreal, Quebec, Canada
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OCOG-2008-ZAMBONEY
Identifier Type: -
Identifier Source: org_study_id